Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2014

01-07-2014 | Original Article

Epstein–Barr Virus (EBV) Related Acute Liver Failure: A Case Series from the US Acute Liver Failure Study Group

Authors: Jessica L. Mellinger, Lorenzo Rossaro, Willscott E. Naugler, Satish N. Nadig, Henry Appelman, William M. Lee, Robert J. Fontana

Published in: Digestive Diseases and Sciences | Issue 7/2014

Login to get access

Abstract

Purpose

Acute liver failure (ALF) is a rare clinical syndrome associated with a high case fatality rate. Asymptomatic primary infection with Epstein–Barr virus (EBV) is common in the general population while acute hepatitis and jaundice are much less common and ALF has been rarely reported. We reviewed the presenting features as well as clinical outcomes amongst consecutive adults with EBV-related ALF.

Methods

Amongst the 1,887 adult ALF patients enrolled into the US ALF Study Group from January 1998 to February 2012, there were four patients (0.21 %) with EBV-related ALF. Diagnostic criteria for acute EBV infection included compatible serologies and/or the detection of EBV-encoded RNA (EBER) in liver tissue.

Results

Median patient age was 30 years (range 18–44); 75 % were male, and only 25 % were immunosuppressed. The median presenting ALT was 504 IU/mL (range 156–4,920), median Alk P was 431 (range 136–1,009), and median bilirubin was 17 mg/dL (range 13–22.1). Liver biopsy findings ranged from cholestasis to submassive necrosis with EBER + staining in two of the three samples tested. Although all of the patients were treated with an antiviral agent, two died of ALF, one underwent liver transplantation (LT) and one survived with supportive care and is well at 5 years. A review of the literature identified four additional LT recipients with favorable long-term outcomes.

Conclusion

Primary EBV infection accounts for <1 % of consecutive adult ALF cases but is associated with a high case fatality rate. LT is associated with favorable short- and long-term outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Polson J, Lee WM. American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.PubMedCrossRef Polson J, Lee WM. American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.PubMedCrossRef
3.
go back to reference Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954.PubMedCrossRef Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954.PubMedCrossRef
4.
go back to reference Levitsky J, Duddempudi AT, Lakeman FD, et al. Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transpl. 2008;14:1498–1504.PubMedCentralPubMedCrossRef Levitsky J, Duddempudi AT, Lakeman FD, et al. Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transpl. 2008;14:1498–1504.PubMedCentralPubMedCrossRef
5.
go back to reference Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.PubMedCentralPubMedCrossRef Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.PubMedCentralPubMedCrossRef
6.
go back to reference Chen EY, Baum K, Collins W, et al. Hepatitis E masquerading as drug-induced liver injury. Hepatology. 2012;56:2420–2423.PubMedCrossRef Chen EY, Baum K, Collins W, et al. Hepatitis E masquerading as drug-induced liver injury. Hepatology. 2012;56:2420–2423.PubMedCrossRef
7.
go back to reference Huang RJ, Varr BC, Triadafilopoulos G. Acute fulminant hepatic failure associated with parvovirus B19 infection in an immunocompetent adult. Dig Dis Sci. 2012;57:2811–2813.PubMedCrossRef Huang RJ, Varr BC, Triadafilopoulos G. Acute fulminant hepatic failure associated with parvovirus B19 infection in an immunocompetent adult. Dig Dis Sci. 2012;57:2811–2813.PubMedCrossRef
8.
go back to reference Kofteridis DP, Koulentaki M, Valachis A, et al. Epstein Barr virus hepatitis. Eur J Intern Med. 2011;22:73–76.PubMedCrossRef Kofteridis DP, Koulentaki M, Valachis A, et al. Epstein Barr virus hepatitis. Eur J Intern Med. 2011;22:73–76.PubMedCrossRef
9.
go back to reference Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis. 2010;50:1439–1447.PubMed Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis. 2010;50:1439–1447.PubMed
10.
go back to reference Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A–E hepatitis. J Infect Dis. 2003;188:1545–1552.PubMedCrossRef Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A–E hepatitis. J Infect Dis. 2003;188:1545–1552.PubMedCrossRef
11.
go back to reference Lee WM, Brown KE, Young NS, et al. Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci. 2006;51:1712–1715.PubMedCrossRef Lee WM, Brown KE, Young NS, et al. Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci. 2006;51:1712–1715.PubMedCrossRef
12.
go back to reference Dumortier J, Mekki Y, Rimmelé T, et al. Hépatite fulminante à virus Epstein–Barr: évolution favorable après transplantation hépatique. Gastroentérologie Clinique et Biologique. 2007;31:725–728.PubMedCrossRef Dumortier J, Mekki Y, Rimmelé T, et al. Hépatite fulminante à virus Epstein–Barr: évolution favorable après transplantation hépatique. Gastroentérologie Clinique et Biologique. 2007;31:725–728.PubMedCrossRef
13.
go back to reference Park HW, Lee SG, Hwang SK, et al. Epstein–Barr virus associated fulminant hepatitis requiring liver transplantation (case report) [abstract]. HPB Off J Int Hepato Pancreato Biliary Assoc. 2011;13:174–244. Park HW, Lee SG, Hwang SK, et al. Epstein–Barr virus associated fulminant hepatitis requiring liver transplantation (case report) [abstract]. HPB Off J Int Hepato Pancreato Biliary Assoc. 2011;13:174–244.
14.
go back to reference Tohyama T, Takada Y, Waianabe J, et al. ABO incompatible living donor liver transplantation saved a child with fulminant hepatic failure caused by primary EBV infection [abstract]. Liver Transpl. 2011;S1:S146. Tohyama T, Takada Y, Waianabe J, et al. ABO incompatible living donor liver transplantation saved a child with fulminant hepatic failure caused by primary EBV infection [abstract]. Liver Transpl. 2011;S1:S146.
15.
go back to reference Feranchak AP, Tyson RW, Narkewicz MR, et al. Fulminant Epstein–Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998;4:469–476.PubMedCrossRef Feranchak AP, Tyson RW, Narkewicz MR, et al. Fulminant Epstein–Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998;4:469–476.PubMedCrossRef
16.
go back to reference Silfeler I, Kurnaz H, Acar Y, et al. EBV-induced fulminant hepatic failure treated with liver transplantation. Pak J Med Sci. 2010;26:971–972. Silfeler I, Kurnaz H, Acar Y, et al. EBV-induced fulminant hepatic failure treated with liver transplantation. Pak J Med Sci. 2010;26:971–972.
17.
go back to reference Suh MY, Wang K, Gutweiler JR, et al. Liver transplantation for Epstein Barr virus (EBV)-related hepatic failure using a graft from hepatitis B core antibody positive (HBcAb+) donor [abstract]. Pediatr Transpl. 2007;11:249. Suh MY, Wang K, Gutweiler JR, et al. Liver transplantation for Epstein Barr virus (EBV)-related hepatic failure using a graft from hepatitis B core antibody positive (HBcAb+) donor [abstract]. Pediatr Transpl. 2007;11:249.
18.
go back to reference Matsusaki T, Morimatsu H, Matsumi J, et al. Two cases of fulminant hepatitis due to Epstein Barr virus [abstract]. Anesth Analg. 2010;110:S286. Matsusaki T, Morimatsu H, Matsumi J, et al. Two cases of fulminant hepatitis due to Epstein Barr virus [abstract]. Anesth Analg. 2010;110:S286.
19.
go back to reference Bakay HK, Silfeler I, Hamilcikan B, et al. EBV-induced fulminant hepatic failure treated with liver transplantation [abstract]. Acta Paediatr. 2008;97:1–259. Bakay HK, Silfeler I, Hamilcikan B, et al. EBV-induced fulminant hepatic failure treated with liver transplantation [abstract]. Acta Paediatr. 2008;97:1–259.
21.
go back to reference Posthuma EF, Westendorp RG, van der Sluys Veer A, et al. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut. 1995;36:311–313.PubMedCentralPubMedCrossRef Posthuma EF, Westendorp RG, van der Sluys Veer A, et al. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut. 1995;36:311–313.PubMedCentralPubMedCrossRef
22.
go back to reference N’guyen Y, Andreoletti L, Patey M, et al. Fatal Epstein–Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn’s disease. J Clin Microbiol. 2009;47:1252–1254.PubMedCentralPubMedCrossRef N’guyen Y, Andreoletti L, Patey M, et al. Fatal Epstein–Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn’s disease. J Clin Microbiol. 2009;47:1252–1254.PubMedCentralPubMedCrossRef
23.
24.
go back to reference Ader F, Chatellier D, Le Berre R, et al. Fulminant Epstein–Barr virus (EBV) hepatitis in a young immunocompetent subject. Med Mal Infect. 2006;36:396–398.PubMedCrossRef Ader F, Chatellier D, Le Berre R, et al. Fulminant Epstein–Barr virus (EBV) hepatitis in a young immunocompetent subject. Med Mal Infect. 2006;36:396–398.PubMedCrossRef
25.
go back to reference Pagidipati N, Obstein KL, Rucker-Schmidt R, et al. Acute hepatitis due to Epstein–Barr virus in an immunocompetent patient. Dig Dis Sci. 2009;55:1182–1185.PubMedCrossRef Pagidipati N, Obstein KL, Rucker-Schmidt R, et al. Acute hepatitis due to Epstein–Barr virus in an immunocompetent patient. Dig Dis Sci. 2009;55:1182–1185.PubMedCrossRef
26.
go back to reference Vine LJ, Shepherd K, Hunter JG, et al. Characteristics of Epstein–Barr virus hepatitis among patients with jaundice or acute hepatitis. Aliment Pharmacol Ther. 2012;36:16–21.PubMedCrossRef Vine LJ, Shepherd K, Hunter JG, et al. Characteristics of Epstein–Barr virus hepatitis among patients with jaundice or acute hepatitis. Aliment Pharmacol Ther. 2012;36:16–21.PubMedCrossRef
27.
go back to reference Suh N, Liapis H, Misdraji J, et al. Epstein–Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients. Am J Surg Pathol. 2007;31:1403–1409.PubMedCrossRef Suh N, Liapis H, Misdraji J, et al. Epstein–Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients. Am J Surg Pathol. 2007;31:1403–1409.PubMedCrossRef
28.
go back to reference Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein–Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879–885.PubMedCrossRef Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein–Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879–885.PubMedCrossRef
29.
go back to reference Markin RS. Manifestations of Epstein–Barr virus-associated disorders in liver. Liver. 1994;14:1–13.PubMedCrossRef Markin RS. Manifestations of Epstein–Barr virus-associated disorders in liver. Liver. 1994;14:1–13.PubMedCrossRef
30.
go back to reference Markin RS, Linder J, Zuerlein K, et al. Hepatitis in fatal infectious mononucleosis. Gastroenterology. 1987;93:1210–1217.PubMed Markin RS, Linder J, Zuerlein K, et al. Hepatitis in fatal infectious mononucleosis. Gastroenterology. 1987;93:1210–1217.PubMed
31.
go back to reference Adams LA, Deboer B, Jeffrey G, et al. Ganciclovir and the treatment of Epstein–Barr virus hepatitis. J Gastroenterol Hepatol. 2006;21:1758–1760.PubMedCrossRef Adams LA, Deboer B, Jeffrey G, et al. Ganciclovir and the treatment of Epstein–Barr virus hepatitis. J Gastroenterol Hepatol. 2006;21:1758–1760.PubMedCrossRef
32.
go back to reference Pisapia R, Mariano A, Rianda A, et al. Severe EBV hepatitis treated with valganciclovir. Infection. 2013;41:251–254.PubMedCrossRef Pisapia R, Mariano A, Rianda A, et al. Severe EBV hepatitis treated with valganciclovir. Infection. 2013;41:251–254.PubMedCrossRef
33.
go back to reference Liapis K, Apostolidis J, Delimpasis S. EBV-associated hemophagocytic syndrome. Am J Hematol. 2011;86:422.PubMedCrossRef Liapis K, Apostolidis J, Delimpasis S. EBV-associated hemophagocytic syndrome. Am J Hematol. 2011;86:422.PubMedCrossRef
Metadata
Title
Epstein–Barr Virus (EBV) Related Acute Liver Failure: A Case Series from the US Acute Liver Failure Study Group
Authors
Jessica L. Mellinger
Lorenzo Rossaro
Willscott E. Naugler
Satish N. Nadig
Henry Appelman
William M. Lee
Robert J. Fontana
Publication date
01-07-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3029-2

Other articles of this Issue 7/2014

Digestive Diseases and Sciences 7/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.